Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743

Friday, May 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CHELMSFORD, Mass., May 29 Magellan Biosciences, anemerging leader in clinical-diagnostics markets worldwide, will featureautomated systems and assays designed to streamline microbiology testing andimprove health outcomes for patients at the 108th meeting of the AmericanSociety for Microbiology (ASM). Magellan subsidiaries, TREK DiagnosticSystems and Dynex Technologies, will share booth 743 at the exhibition, whichruns Monday through Wednesday, June 2-4, 2008, at the Boston Convention andExhibition Center. TREK scientists are also presenting a number of technicalposters during the conference.

TREK will highlight its new Sensititre(R) Gram positive all-in-one dry,microbroth dilution plates -- the only MIC plates cleared by the FDA forD-Test and Cefoxitin screening, Daptomycin and Vancomycin confirmation, aswell as numerous other antimicrobics. The D-Test detects inducible resistanceto Clindamycin -- a drug commonly used for treating community-acquiredMethicillin Resistant Staphylococcus aureus (MRSA), particularly in pediatricpopulations. The Cefoxitin Screen procedure is the most-sensitive testavailable to detect low-level Methicillin and Oxacillin (MRSA) resistance. Inaddition, TREK will demonstrate its new Vizion(TM) System*, which addseasy-to-read digital imaging capability to the company's Sensititre(R)Automated Susceptibility and Identification Testing System. Vizion is theonly system that enables users to save and store digital images ofsusceptibility results for consultations, quality control, and training. TheSensititre/Vizion system enables easy and accurate antimicrobial-resistancedetection of all organism groups, including fastidious isolates, such asHaemophilus, Streptococcus, Mycobacteria, and yeast. The award-winningVersaTREK(R) Automated Microbial Detection System will also be on view.

Dynex will feature its much-heralded DS2(R) automated two-plate ELISAprocessing system, which provides full walk-away capability to busymicrobiology labs. Reliable, cost-effective, and easy to use and maintain,the DS2 packs full automation power in the smallest footprint available. Thesystem quickly and easily processes two 96-well microplates and up to 12different assays simultaneously and features the most user-friendly controlsystem available, chain of custody, and instrument diagnostics.

"MRSA is a growing concern in healthcare," said Magellan President andCEO, Robert J. Rosenthal, Ph.D. "Managers of microbiology labs are lookingfor integrated systems that streamline testing, take the guesswork out ofidentifying often difficult-to-read results, reduce errors from manualmethods, and provide faster turnaround times at a lower cost per result.TREK's Sensititre System delivers, testing for the widest range of resistantorganisms in one platform." Regarding the Dynex DS2, Dr. Rosenthal remarked,"Doctors rely on fast, accurate, and reliable results from diagnostic tests tomake good treatment decisions. Today, there's a critical shortage ofqualified laboratory personnel, and most hospital-based microbiology labs haveneither the space nor throughput requirements to justify large-scale automatedsystems. That's why Dynex designed the easy-to-use DS2 system, which deliverssample-in/results-out automation of virtually any ELISA microplate assay."

About Magellan Biosciences (

Magellan serves the worldwide clinical-diagnostics market with rapidpoint-of-care analyzers and automated systems for hospital-based labs andnear-patient testing. Scientists use the company's discovery systems andsensors for cutting-edge research to develop a new understanding of health andillness -- from disease pathology to biomarker identification. Magellandesigns all its systems, sensors, and consumables to deliver better,more-reliable results. And better results help drive improved healthoutcomes: earlier, more-accurate dia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store